June 2026 Research Update

This month added a clearer signal that a common orthopedic approach for knock-knee-type alignment can work in children with mucopolysaccharidoses, even though their bones can look and grow differently. In one center's experience, correction of femur and tibia alignment after tension-band plates looked broadly similar in patients with Hurler or Morquio syndrome compared with children whose valgus deformity had an idiopathic (typical, unknown-cause) origin. This matters because it suggests the basic idea of guided growth may still apply in MPS, rather than being automatically less effective. [1]

The study compared how much alignment changed over time and how often full correction was reached. The authors reported no statistically significant differences between the MPS group and the idiopathic group in correction outcomes or correction rates, based on follow-up X-rays taken at intervals. Because this was a small, retrospective experience from one institution, it describes what happened in that setting rather than proving what will happen for every child. [1]

For families dealing with leg alignment problems in Hurler syndrome, this month provides human data suggesting that guided growth using tension-band plates may achieve correction that is not clearly worse than in children without MPS. It does not say who is most likely to reach full correction, or how results compare with other surgical options, but it helps reduce uncertainty about whether this approach can work at all in MPS-affected bone. This is evidence from routine care at one hospital, so it may matter now as background understanding, while stronger answers would need larger and more diverse patient groups. [1]

This month, the new clinical information in Hurler syndrome (MPS I) came from case reports, which are detailed stories from one person and are meant to flag possibilities rather than give averages. Together, these reports show that adults with MPS I can have unexpected or easily missed issues that fall outside the classic picture, including eye disease without the usual corneal clouding and complex liver inflammation when another infection is present. The value here is in expanding what patients and caregivers may recognize as "could be related," not in predicting how common these events are. [2] [3]

One report described a 71-year-old woman diagnosed with MPS I who had retinal degeneration while her corneas stayed clear. Detailed eye testing showed widespread retinal thinning and reduced electrical responses from the retina, and genetic testing identified two IDUA variants supporting the diagnosis. In plain language, this adds a reminder that vision problems in MPS I are not always driven by cloudy corneas and may sometimes involve the retina more strongly, especially in atypical later-life presentations. [3]

A separate report described a 28-year-old man with Hurler syndrome who developed liver injury after taking amoxicillin while also having an acute hepatitis C infection. The authors judged the antibiotic-related liver injury as "probable" using a structured scoring method and biopsy findings, and the person improved over weeks with supportive hospital treatments before later clearing hepatitis C after antiviral therapy. This case highlights that when multiple causes of liver inflammation overlap, careful evaluation may be needed to sort out what contributed, but it cannot show how often this happens in Hurler syndrome. [2]

For patients and caregivers, these single-person reports mainly matter as awareness-building rather than something that changes standard care. They help clarify that MPS I can sometimes show up with less typical adult features (like retina-predominant eye disease) and that serious but reversible medical episodes (like liver injury) can occur in complicated settings. What remains uncertain is how common these situations are and which patients are at higher risk, because case reports cannot answer frequency questions. The main near-term value is adding specific examples that researchers and clinicians can look for in larger studies later. [2] [3]

This month included two studies aimed at the long-term pipeline: making early detection more reliable and exploring a less invasive way to deliver enzyme therapy. Both point in a positive direction for research, but they are not the kind of evidence that can tell families what outcomes to expect right now. One effort focused on improving laboratory "practice samples" for newborn screening labs, and the other tested an oral enzyme formulation in cells and mice. [4] [5]

For screening, a quality-assurance program developed dried blood spot materials that laboratories can use to check whether their tests correctly flag several lysosomal diseases, including MPS I. After early prototypes that had some incorrect assessments, later pilot rounds reached near-perfect accuracy, and a broader deployment reported that most results were acceptable, with remaining errors linked to handling or reporting issues. In plain language, this work aims to make it less likely that screening programs miss or mis-handle test performance over time, even though it does not measure real-world newborn outcomes directly. [4]

For future treatment delivery, a preclinical study packaged alpha-L-iduronidase (the missing enzyme in MPS I) into lipid nanoparticles designed to survive the gut and be absorbed. In patient-derived cells, the oral formulation corrected enzyme activity and lowered stored sugars to a similar degree as intravenous enzyme in that laboratory setting, and in MPS I knockout mice it spread to multiple tissues, including brain and bone. These results are an early signal that oral delivery might be possible in principle, but the study did not report human safety or symptom outcomes. [5]

For families, the screening study matters in the background because reliable lab proficiency testing supports consistent newborn screening performance across many locations, including for MPS I. The oral enzyme study is earlier-stage research that may matter later if it can be translated safely to people, especially because it reported tissue distribution in mice that included the brain and bone. What remains unknown is whether an oral approach can deliver enough enzyme safely and consistently in humans, and whether it would improve day-to-day health outcomes. For now, these studies mostly add confidence about research direction rather than providing clinical results. [4] [5]